Will GLP-1 Demand Drive MCK's Top Line This Earnings Season?

McKesson (MCK) is set to report Q1 fiscal 2026 results on August 6, with analysts anticipating $8.23 EPS, a 4.4% year-over-year improvement, on revenues of $96.1 billion, surging 21.2%. Top-line growth is primarily driven by robust demand for GLP-1 weight loss drugs and specialty pharmaceuticals within its U.S. Pharmaceutical segment, alongside a rebound in primary care visits. However, earnings face headwinds from lower-margin GLP-1 sales, reduced COVID-19 vaccine distribution, and the impact of recent European and Canadian divestitures, while the company's negative Earnings ESP suggests a potential earnings miss despite a Zacks Rank #2.

Analysis

McKesson Corporation (MCK) is approaching its first-quarter fiscal 2026 earnings report with a dual-sided outlook, characterized by robust revenue expansion and significant margin pressure. The consensus estimate projects a 21.2% year-over-year surge in revenue to $96.1 billion, primarily driven by its U.S. Pharmaceutical segment, which is forecast to grow 21%. This top-line momentum is fueled by the high-volume distribution of GLP-1 weight-loss drugs and sustained demand for specialty pharmaceuticals, particularly oncology treatments. However, this growth narrative is tempered by profitability concerns, as the consensus earnings per share (EPS) estimate of $8.23 implies a much more modest 4.4% year-over-year improvement. The key headwind is gross margin compression resulting from the sales mix shifting toward lower-margin GLP-1 products. Additional pressures include declining COVID-19 vaccine distribution volumes, the dilutive impact from the divestiture of European and Canadian operations, and unfavorable formulary changes from a national retail customer. While the company holds a Zacks Rank #2 (Buy), the quantitative model points to a negative Earnings ESP of -0.92%, suggesting a heightened risk of an earnings miss.

Key Decisions for Investors

• Investors should closely scrutinize gross margin performance to determine if the impressive 21.2% projected revenue growth is translating into sustainable profit, given the known pressure from lower-margin GLP-1 drug sales.
• Pay close attention to management's guidance regarding the impact of recent divestitures on future earnings and their strategy for offsetting margin erosion from the current sales mix.
• Given the negative Earnings ESP of -0.92%, which signals a potential earnings miss, it may be prudent to hedge positions or exercise caution ahead of the August 6 report, as a strong revenue print could be overshadowed by a bottom-line disappointment.
• Consider the relative strength of peers like Cardinal Health (CAH), which the report notes has a positive Earnings ESP, for investors seeking potentially more favorable near-term earnings surprise catalysts within the sector.